Baird’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Baird’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-203,409	Closed	-$31.8M	–	1349
2014 Q3	$31.8M	Buy	+203,409	New	+$29.5M	0.45%	80

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baird's SLXP Position: Q4 2014 in Review

Baird sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 203,409 shares — an estimated $31.8M sold.

Baird first reported a position in SLXP in Q3 2014 and held it in 1 quarter. The position peaked at $31.8M in Q3 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

Baird reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
Baird sold 203,409 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $31.8M.
Baird first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2014 and held it in 1 quarter.
Baird's SALIX PHARMACEUTICALS LTD DEL position peaked at $31.8M in Q3 2014.
346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Baird's 13F filing for Q4 2014, filed 12 Feb 2015.